€ 0.31
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only